Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review

作     者：Cheng-Ming Li Zhi-Chao Liu You-Ting Bao Xin-Dong Sun Lin-Lin Wang 

作者机构：School of Medicine and Life Sciences University of Jinan-Shandong Academy of Medical Sciences Department of Radiation Oncology Shandong Cancer Hospital Affiliated to Shandong University Shandong Academy of Medical Sciences Department of Oncology Weifang Medical University School of Medicine Shandong University 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2017年第23卷第41期

页      面：7478-7488页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by The National Natural Science Foundation of China,No.81402299 the Project of Postdoctoral Innovation of Shandong Province,No.201501010 the Project of Postdoctoral Science Foundation of China,No.2016M590640 

主　　题：Anti-angiogenesis Apatinib Pancreatic cancer Targeted therapy Vascular endothelial growth factor receptor-2 

摘      要：Chemotherapy has limited efficacy in the treatment of advanced and metastatic pancreatic cancer(PC), and has serious side effects. The development of novel effective agents, especially targeted therapy, is essential for patients with PC. We present a 58-year-old Chinese woman initially diagnosed with locally advanced PC. As the disease progressed to Stage Ⅳ, the patient was unable to tolerate chemotherapy after the fourth-line treatment. She was then treated with apatinib, a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 and achieved a progression-free-survival of 7 mo. All drug-related side effects were well controlled with medication. To the best of our knowledge, this is the first case of PC which responded to apatinib. Considering this remarkable response, apatinib may be a promising agent in the treatment of PC. We also reviewed the literature on chemotherapy and targeted therapy, especially the anti-angiogenesis therapy for patients with PC, and investigated the effect of apatinib in other solid tumors as well.